# Andromeda Surgical

**Source:** https://geo.sig.ai/brands/andromeda-surgical  
**Vertical:** Healthcare  
**Subcategory:** General  
**Tier:** Emerging  
**Website:** andromedasurgical.com  
**Last Updated:** 2026-04-14

## Summary

Surgical robotics company achieving world's first robotic-assisted HoLEP for prostate treatment; YC-backed targeting $10B+ urology market with Richard Wolf and Quanta System partnerships.

## Company Overview

Andromeda Surgical is a surgical robotics company developing autonomous robots for urological procedures — specifically targeting the HoLEP (Holmium Laser Enucleation of the Prostate) procedure used to treat benign prostatic hyperplasia (BPH, enlarged prostate), a condition affecting 50%+ of men over 50. Founded in 2023 by CEO Nick Damiano and CTO Kartik Tiwari and a Y Combinator S23 graduate, Andromeda raised $500,000 in seed funding from CoreNest and YC, and achieved the world's first robotic-assisted HoLEP procedure in December 2024 — a significant clinical milestone.\n\nAndromeda's surgical robot assists urologists performing HoLEP procedures by providing precise laser energy delivery and tissue manipulation, targeting the improvement in procedural consistency and outcome reproducibility that robotic assistance provides across varying surgeon skill levels. HoLEP is considered the gold standard treatment for BPH but has a steep learning curve — it requires 30-50+ procedures to achieve proficiency, limiting its adoption to high-volume academic medical centers. Andromeda's robotic assistance aims to make HoLEP accessible at community hospitals by reducing the expertise barrier.\n\nIn 2025, Andromeda competes in the surgical robotics market with Intuitive Surgical (da Vinci for soft tissue surgery), GYRUS Medical (urological instruments), and emerging robotic surgery startups targeting different procedural niches for surgical automation. The global urology surgery robotics market represents a $3+ billion opportunity, with the broader HoLEP addressable market estimated at $10+ billion. Strategic partnerships with Richard Wolf (endoscopy equipment) and Quanta System (laser platforms) provide Andromeda with established distribution channels and clinical credibility. The 2025 strategy focuses on additional clinical procedures to build the safety evidence required for FDA clearance, expanding from the first-in-human milestone toward a pivotal trial for regulatory submission.

## Frequently Asked Questions

### What is Andromeda Surgical?
Andromeda Surgical is a San Francisco-based healthcare tech company founded in 2023 that develops autonomous surgical robots for urology procedures. The company participated in Y Combinator's S23 batch and is led by CEO Nick Damiano and CTO Kartik Tiwari.

### What products and services does Andromeda Surgical offer?
Andromeda Surgical develops autonomous surgical robotic systems specifically designed for urology procedures. The company achieved the world's first robotic-assisted HoLEP procedure in December 2024 at Universidad Católica Chile.

### Who is Andromeda Surgical's target market?
Andromeda Surgical targets the urology market, focusing on procedures like HoLEP (Holmium Laser Enucleation of the Prostate). The company is addressing a $3 billion+ HoLEP market within a broader $10 billion+ urology opportunity.

### When was Andromeda Surgical founded?
Andromeda Surgical was founded in 2023 and participated in Y Combinator's Summer 2023 (S23) batch.

### Where is Andromeda Surgical located?
Andromeda Surgical is based in San Francisco, California, United States.

### How much funding has Andromeda Surgical raised?
Andromeda Surgical has raised $500,000 total over 2 rounds. The seed round was completed in November 2024 and was led by CoreNest, with participation from Y Combinator and WestWave Capital.

### What are Andromeda Surgical's key achievements?
Andromeda Surgical achieved the world's first robotic-assisted HoLEP procedure in December 2024 at Universidad Católica Chile. In March 2025, the company announced strategic partnerships with Richard Wolf and Quanta System to accelerate clinical development and global market access.

### What technology approach does Andromeda Surgical use?
Andromeda Surgical develops autonomous surgical robotic systems. The founding team brings expertise from medtech and autonomous vehicles backgrounds, with 3 founders including 2 who previously went through Y Combinator.

### Who founded Andromeda Surgical?
Andromeda Surgical was founded by Nick Damiano (CEO) and Kartik Tiwari (CTO), along with a third founder. Two of the three founders have previous Y Combinator experience.

### What are Andromeda Surgical's recent developments?
Recent developments include completing a $500K seed round in November 2024, achieving the world's first robotic-assisted HoLEP procedure in December 2024, and announcing partnerships with Richard Wolf and Quanta System in March 2025. These partnerships aim to accelerate clinical development and expand global market access.

## Tags

healthtech, b2b, ai-powered, automation, global

---
*Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*